COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
The Chinese medicine industry also needs a "supply side reform"
A few days ago, the State Council issued the Outline of the Strategic Plan for the Development of Traditional Chinese Medicine, and the Chinese Medicine Development Plan was upgraded to the national strategy. The "Outline" pointed out that by 2020, the Chinese medicine industry has become one of the important pillars of the national economy. For China's traditional Chinese medicine industry, this is undoubtedly a "timely rain." For a long time, problems such as lack of quality standards, weak patent awareness, and lagging technology research and development have plagued China's traditional Chinese medicine industry. The international Chinese medicine market has been monopolized by “foreign Chinese medicine”, and the domestic market is increasingly affected by “foreign Chinese medicine”. The road is a long way to go.
Many industry insiders said that they hope to implement detailed and operability policy rules in the implementation of the "Outline" in improving the quality standards of Chinese medicines, protecting intellectual property rights of Chinese medicines, and encouraging enterprises to innovate in science and technology. The reform began, let the ancestors of Chinese medicine passed down to the world, and achieve a gorgeous turn.
First, develop a detailed quality standard system for Chinese medicine. You Hongtao, chairman of Watson Pharmaceutical Group, suggested that the traditional Chinese herbal medicine should pay attention to the authenticity of raw materials. “Daoji Medicine” is the first guarantee for high-quality products, and should deal with all aspects of Chinese herbal medicine planting, such as planting density per mu. Detailed regulations are made on the use of water, pesticides and fertilizers.
At the same time, Bai Lixi, Chairman of the Board of Directors of Taiji Group, suggested that the quality standards of Chinese medicine products should not only analyze the pharmacological components of the compound Chinese medicine, but also include what kind of ingredients are effective for various diseases, and how the ratio between the various ingredients is Combination, what treatment effect on what disease, etc. Production process standards, production base standards, management standards, packaging standards, etc. also need to be clear. In addition, while improving the quality standard system, it is necessary to improve relevant laws and regulations, strengthen process supervision, and severely punish violations such as the use of prohibited pesticides and unclear labeling of ingredients.
Second, strengthen the protection of intellectual property rights in the Chinese medicine industry. On the one hand, it may consider establishing a special institution for the protection of Chinese medicine and intellectual property rights, conducting intellectual property research, guiding enterprises to raise awareness of intellectual property protection, and attaching great importance to the importance of patents as intangible assets from research, business strategies and development strategies; Drawing on the relevant laws of other countries, researching and formulating an intellectual property system that conforms to the characteristics of Chinese medicine and is in line with international practice, shortens the patent examination and approval cycle, expands the scope of protection, and at the same time is in line with international standards, seeking an international basis for the protection of traditional Chinese medicine intellectual property rights.
Third, introduce a package of operability policy rules and increase support for enterprise innovation. For example, at present, most of the scientific and technological innovations of Chinese medicine enterprises are completed by the organization's own organizational strength, and the scientific research personnel are scattered in different research institutes. It is difficult to form a joint force. The national team of Chinese medicine research and development can be established, and social intellectual resources can be integrated to create a “wallless”. Research Institute."
At the same time, it is necessary to break down the institutional and institutional barriers that dampen the innovation enthusiasm of enterprises, and support and encourage enterprises to face innovation at the policy level. For example, the state should not only support the development of new drugs, but also continue to provide strong support after the products enter the market, such as increasing incentives for enterprises that achieve innovation breakthroughs and obtaining core patents, and support new drugs to enter the medical insurance catalogue and the basic drug list. All provinces and cities have priority bidding for new drugs.